Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2013

01-10-2013 | Review

Prognostic significance of cyclooxygenase-2 in osteosarcoma: a meta-analysis

Authors: Guangjun Jiao, Tingting Ren, Qunshan Lu, Yifeng Sun, Zhiyuan Lou, Xianbo Peng, Weimin Liang, Wei Guo

Published in: Tumor Biology | Issue 5/2013

Login to get access

Abstract

Published studies researching the prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with osteosarcoma are inconclusive and heterogeneous. We conducted a meta-analysis to assess its prognostic value more precisely. The pooled odds ratios (ORs) or hazard ratios (HRs) with corresponding 95 % confidence intervals (CIs) were calculated to evaluate the effects. Fourteen studies with 735 osteosarcoma patients were included to estimate the relationship between COX-2 and metastasis of tumor, clinical stage, and 3-year overall survival. High expressions of COX-2 predicted neoplasm metastasis (OR = 1.891, 95 % CI 1.276–2.803, P = 0.002), advanced clinical stage (OR = 1.801, 95 % CI 1.257–2.581, P = 0.001). In addition, high COX-2 expression tended to be associated with a poor 3-year survival (HR = 1.741, 95 % CI 0.762–3.979, P = 0.188), but the difference was not significant. Therefore, this meta-analysis demonstrated that high COX-2 expression might be an unfavorable prognostic effect in osteosarcoma.
Appendix
Available only for authorised users
Literature
1.
Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154–61.CrossRefPubMed
2.
Picci P, Mercuri M, Ferrari S, Alberghini M, Briccoli A, Ferrari C, et al. Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol. 2010;21:1366–73.CrossRefPubMed
3.
Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005;23:2840–55.CrossRefPubMed
4.
Denkert C, Kobel M, Berger S, Siegert A, Leclere A, Trefzer U, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res. 2001;61:303–8.PubMed
5.
Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306–11.PubMed
6.
Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res. 2001;7:429–34.PubMed
7.
Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 2001;91:333–8.CrossRefPubMed
8.
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705–16.CrossRefPubMed
9.
Sawaoka H, Kawano S, Tsuji S, Tsujii M, Gunawan ES, Takei Y, et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol. 1998;274:G1061–7.PubMed
10.
Masi L, Recenti R, Silvestri S, Pinzani P, Pepi M, Paglierani M, et al. Expression of cyclooxygenase-2 in osteosarcoma of bone. Appl Immunohistochem Mol Morphol. 2007;15:70–6.CrossRefPubMed
11.
Ma J, Chen X, Zhong Y, Li D, Xiao Z. Expression and significance of COX-2 and VEGF in osteosarcoma. Shandong Med J. 2011;51:7–9.
12.
Boulytcheva IV, Soloviev YN, Kushlinskii NE, Mahson AN. Expression of molecular markers in the tumor and survival prognosis in osteosarcoma. Bull Exp Biol Med. 2010;150:237–42.CrossRefPubMed
13.
Li Y, Xiao Y, Wang W. Expression of cox-2 and ki-67 in osteosarcoma and their clinical significance. Chin J Gen Pract. 2010;8:274–7.
14.
Xu X, Huang G, Liu J, Li L, Luo Y. Expression of PTEN, COX-2 and MMP-9 in osteosarcoma and its clinical significance. J Clin Res. 2010;27:820–3.
15.
Urakawa H, Nishida Y, Naruse T, Nakashima H, Ishiguro N. Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study. Clin Orthop Relat Res. 2009;467:2932–8.PubMedCentralCrossRefPubMed
16.
Rodriguez NI, Hoots WK, Koshkina NV, Morales-Arias JA, Arndt CA, Inwards CY, et al. COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. J Pediatr Hematol Oncol. 2008;30:507–12.PubMedCentralCrossRefPubMed
17.
Geng Y, Wan C, Chen P. Expressions of COX-2 and HF-1α and their relationship with clinicopathologic characteristics of osteosarcoma. Tumor. 2008;28:427–30.
18.
Huang J, Shi Y, Xiang Z. The expression of COX-2 in osteosarcoma and its clinical significance. J Med Theor and Prac. 2008;21:1134–6.
19.
Zhang X, Cai W. Significance of expression of COX-2 and Fas in cases of osteosarcoma. J Clin Exp Med. 2008;7:45–7.
20.
Ouyang Z, Wang S, Kang X, Wang C, Wang J, Guo H. Expression of cyclooxygenase-2 mRNA, cd105mRNA, and the relation between cyclooxygenase-2mRNA and Cd 105mRNA in osteosarcoma. Chin J Bone Tumor Bone Dis. 2007;6:226–32.
21.
Liao Y, Li F, Hu X. Expression and clinical significance of OPN and COX-2 in osteosarcoma. Chin-Ger J Clin Oncol. 2007;6:378–82.CrossRef
22.
Zhu Y, Chi Y, Wang Y, Fan G. Study of expression and their relationship of COX-2 and MMP-2 in osteosarcoma. J Pract Oncol. 2005;19:91–4.
23.
Jiang Y, Yang S, Liu Y. Expression of cyclooxygenase 2 in osteosarcoma and its significance. Central China Med J. 2004;28:109–10.
24.
Dickens DS, Rafal Kozielski R, Leavey PJ, Timmons C, Cripe TP. COX-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol. 2003;25:282–5.CrossRefPubMed
25.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.PubMedCentralCrossRefPubMed
26.
27.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.
28.
29.
Mascaux C, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, et al. Has COX-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br J Cancer. 2006;95:139–45.PubMedCentralCrossRefPubMed
30.
Jamieson NB, Carter CR, McKay CJ, Oien KA. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res. 2011;17:3316–31.CrossRefPubMed
31.
Glover JA, Hughes CM, Cantwell MM, Murray LJ. A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer. Br J Cancer. 2011;105:13–7.PubMedCentralCrossRefPubMed
32.
Huang M, Chen Q, Xiao J, Liu C, Zhao X. Prognostic significance of cyclooxygenase-2 in cervical cancer: a meta-analysis. Int J Cancer. 2013;132:363–73.CrossRefPubMed
Metadata
Title
Prognostic significance of cyclooxygenase-2 in osteosarcoma: a meta-analysis
Authors
Guangjun Jiao
Tingting Ren
Qunshan Lu
Yifeng Sun
Zhiyuan Lou
Xianbo Peng
Weimin Liang
Wei Guo
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0998-2

Other articles of this Issue 5/2013

Tumor Biology 5/2013 Go to the issue

Research Article

CARMA3 overexpression accelerates cell proliferation and inhibits paclitaxel-induced apoptosis through NF-κB regulation in breast cancer cells

Research Article

Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors

Research Article

Effect of miR-335 upregulation on the apoptosis and invasion of lung cancer cell A549 and H1299

Research Article

The efficacy of combination therapy using adeno-associated virus-mediated co-expression of apoptin and interleukin-24 on hepatocellular carcinoma

Review

A comparative overview of general risk factors associated with the incidence of colorectal cancer

Research Article

CCL19/CCR7 upregulates heparanase via specificity protein-1 (Sp1) to promote invasion of cell in lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits